Research offers promise for treating schizophrenia


A team led by Gregory Strauss published a study confirming that successfully treating the symptom avolition—reduced motivation—has a positive effect on other negative symptoms of schizophrenia. The results, published in Schizophrenia Bulletin, were based on a phase 2b trial of the compound roluperidone by Minerva Neurosciences.

The study results indicated that avolition is a highly central domain within the negative symptom construct, suggesting that the other negative symptoms are tightly coupled to this domain, and if it is treated successfully, the entire constellation of negative symptoms might improve.